Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Entecavir comparable to tenofovir for treatment-naïve chronic hepatitis B patients

26 Aug 2019

Entecavir and tenofovir deliver similar prognostic benefits in chronic hepatitis B (CHB) patients naïve to any treatment, a new study has shown.

Researchers enrolled 2,897 CHB patients who were given either entecavir (n=1,484; mean age, 48.2±11.5 years; 59.9 percent male) or tenofovir (n=1,413; mean age, 48.8±12.0 years; 64.6 percent male) as first-line antiviral agents. Patients with hepatocellular carcinoma (HCC) or decompensated cirrhosis were ineligible. Study outcomes included the cumulative probabilities of HCC and death, or the need for orthotopic liver transplant (OLT).

In the overall study population, 240 participants developed HCC, resulting in an incidence rate of 8.3 percent. Analysis according to treatment arms showed that the 1-, 3- and 5-year cumulative HCC risks in the entecavir group were 1.0 percent, 4.8 percent and 9.3 percent, respectively. Corresponding values in the tenofovir group were 1.0 percent, 4.7 percent and 7.7 percent (p=0.517).

Multivariate analysis revealed no significant difference in HCC risk between the two groups (adjusted hazard ratio [HR], 0.975, 95 percent CI, 0.747–1.272; p=0.852).

A similar trend was reported for death and OLT, which was reported in 2.5 percent (n=72) of the entire cohort. The respective cumulative risk rates at 1, 3 and 5 years were 0.5 percent, 1.8 percent and 2.6 percent in the entecavir group, and 0.2 percent, 1.4 percent and 2.5 percent in the tenofovir group (p=0.981).

The likelihood of death or OLT was likewise comparable between treatment arms (adjusted HR, 1.202, 0.745–1.939; p=0.451).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.